Making top-quality cancer care accessible to all.100% free, no account required.

Targeting Side Effects of Cancer Immunotherapy for Better Patient Comfort

NCT06673329 · Recruiting
About this trial

This study looks at how well brodalumab works to help patients with side effects from cancer immunotherapy. These side effects happen when the immune system is activated after treatment. The goal is to find a safe way to control these side effects and improve patients' comfort. Brodalumab is already used for other conditions where the immune system is active against the body, and researchers hope it can help here too.

Locations and contact

This trial is running at 1 location in the United States. It is currently recruiting.

United States1 location · 1 recruiting
  • Columbia University Irving Medical CenterNew York, New YorkRecruiting
Who to ask about joining
Who can join

Adults over 18 years old may join if they have a side effect from cancer treatment that is thought to be caused by the immune system. They must also have had prior treatment with steroids for these side effects. Patients currently being treated with curative intent or who have certain health conditions may not be able to participate. The trial team will confirm eligibility.

What happens during the trial

Participants will receive brodalumab, an injection under the skin, for 24 weeks. They will be monitored closely through visits and check-ups, which may include telemedicine appointments. Everyone will receive the same treatment, and they will have assessments to see how well the treatment is working and if there are any side effects.

The trial team

The trial is led by Dr. Brian Henick from Columbia University. Bausch Health Americas, Inc. is also involved in this study.

Important dates

The trial started on March 11, 2025, and is expected to finish by November 2027. It is currently enrolling new participants.

Additional information

The trial ID is NCT06673329. It is a Phase 1 study, which means researchers are looking at how well the treatment works and its safety. This study is regulated by the FDA, and they hope to include about 11 participants.

Similar trials

Other recruiting trials for the same condition, with the eligibility rules written in plain language.

Browse similar trials
Talk to a specialist

Find a top oncologist who can tell you whether a trial is a sensible option for you.

Find a doctor
Cancer hospitals

The cancer centers running studies like this one, and what each is known for.

Browse hospitals